I advised people who were trying to buy the dip thinking it would come back to stay away. I then played the equivalent of a scalp on a very short term setup with less than .0001% of my account value while outlining the risks and that it was a pure gamble. But you are correct, I did trade something I advised people to stay away from.Brian Earl Spilner said:
Also for someone who so ardently told people to stay far away from SMCI, then turned around and bought SMCI options the following week, it's hard to take any of your advice seriously after that.
and thought I was back in 2022. There are no forever holds in leveraged products. That's my point. You've gotten very good at swing trading and I'd hate for you to lose money by abandoning risk management with ANY money by dumping it into an LETF.Quote:
What I'll probably do is take a chunk of what I currently use in my swing trading and dump it in there as a forever hold.
what happens if/when buffett dies?Brian Earl Spilner said:
You're comparing TSLA, a notoriously volatile stock, to BRK.B, one of the safest and most stable stocks on the market, with a beta below 1.
So it's a false equivalency.
Yes, decay exists. But it would affect something like TSLA exponentially more than a BRK.B.
LatinAggie1997 said:
Did anybody buy Microstrategy months ago?
I posted about it after that big dip and Saylor issued more preferred stock to buy the dip.
From under $140 to $360.
If only I wasn't a lol poor and could have bought a big chunk.
sts7049 said:what happens if/when buffett dies?Brian Earl Spilner said:
You're comparing TSLA, a notoriously volatile stock, to BRK.B, one of the safest and most stable stocks on the market, with a beta below 1.
So it's a false equivalency.
Yes, decay exists. But it would affect something like TSLA exponentially more than a BRK.B.
What exactly are you hearing? Do you own it?JH06 said:
Anyone in on ALT? Hearing some good things in their future.
Quote:
GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
"In the third quarter, we reached several important milestones, most notably the completion of enrollment in the Phase 2b IMPACT trial of pemvidutide in MASH, positioning us to report top-line efficacy data in the second quarter of 2025," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Further, we successfully completed our End-of-Phase 2 meeting with the FDA for the pemvidutide Phase 3 obesity program, gaining agreement on the design of the pivotal studies as well as the measures of efficacy and safety."
Dr. Garg continued, "The Phase 3 program is designed to leverage the key attributes of pemvidutide, including the effects of balanced GLP-1/glucagon dual agonism in subjects with overweight and obesity. The program will include four pivotal trials with a primary efficacy endpoint of weight loss and will evaluate the effects of pemvidutide on principal co-morbidities of obesity, including elevated serum lipids and excess liver fat. The program will also assess the preservation of lean mass and its impact on subjects at risk for loss of physical function and other complications of sarcopenia."
"At the 60th Annual Meeting of the European Association for the Study of Diabetes, we presented compelling data from our Phase 2 MOMENTUM trial of pemvidutide in obesity, which highlighted its class-leading preservation of lean mass and preferential reduction in visceral adipose tissue, both of which are important differentiators for pemvidutide," said Scott Harris, M.D., Chief Medical Officer of Altimmune. "We also remain on-track to submit an IND application this quarter for the first of up to three additional indications for pemvidutide, with the trial expected to initiate in the first half of 2025."
Dr. Garg concluded, "The data we have generated to date, coupled with the multiple key inflection points on the horizon, give us confidence that 2025 will be a transformational year for pemvidutide, and for Altimmune."
I don't own ALT but I own 89 Bio who is also involved in MASH research. It's done very well over the past month. Friend got me into that.JH06 said:
Anyone in on ALT? Hearing some good things in their future.
Heineken-Ashi said:What exactly are you hearing? Do you own it?JH06 said:
Anyone in on ALT? Hearing some good things in their future.Quote:
GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
"In the third quarter, we reached several important milestones, most notably the completion of enrollment in the Phase 2b IMPACT trial of pemvidutide in MASH, positioning us to report top-line efficacy data in the second quarter of 2025," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Further, we successfully completed our End-of-Phase 2 meeting with the FDA for the pemvidutide Phase 3 obesity program, gaining agreement on the design of the pivotal studies as well as the measures of efficacy and safety."
Dr. Garg continued, "The Phase 3 program is designed to leverage the key attributes of pemvidutide, including the effects of balanced GLP-1/glucagon dual agonism in subjects with overweight and obesity. The program will include four pivotal trials with a primary efficacy endpoint of weight loss and will evaluate the effects of pemvidutide on principal co-morbidities of obesity, including elevated serum lipids and excess liver fat. The program will also assess the preservation of lean mass and its impact on subjects at risk for loss of physical function and other complications of sarcopenia."
"At the 60th Annual Meeting of the European Association for the Study of Diabetes, we presented compelling data from our Phase 2 MOMENTUM trial of pemvidutide in obesity, which highlighted its class-leading preservation of lean mass and preferential reduction in visceral adipose tissue, both of which are important differentiators for pemvidutide," said Scott Harris, M.D., Chief Medical Officer of Altimmune. "We also remain on-track to submit an IND application this quarter for the first of up to three additional indications for pemvidutide, with the trial expected to initiate in the first half of 2025."
Dr. Garg concluded, "The data we have generated to date, coupled with the multiple key inflection points on the horizon, give us confidence that 2025 will be a transformational year for pemvidutide, and for Altimmune."
I did in my Roth; thanks for postingRightWingConspirator said:
Anyone jump into MELI a few days ago when I posted about it? I think it's up some $150 points in about a week. Long term hold for me and added more.
Miners have been underperforming since the beginning of the year. It's why I'm bullish, yet conservatively so and willing to bail the second something doesn't smell right. I think you are starting to see the effect of debt accumulation, share dilution, cost and difficulty of mining since the halving, and the big one..Number Monkey said:
Anyone understand why CLSK is down so much today while BTC is up? Seems weird...
DC901 said:
Anyone got a good read on Powl? Looking to buy back in during a dip.
Bagholder, from a while agoconfucius_ag said:
Old name from a while ago is trying to break out above 200ma ------ASAN
550 shares collecting dust here too. what's the news?South Platte said:Bagholder, from a while agoconfucius_ag said:
Old name from a while ago is trying to break out above 200ma ------ASAN
No clue. It's in an old Schwab Roth that I no longer fund and is my only holding with Schwab. I know I bought 100 shares somewhere around $20. I'll check the quote once a month to see if he's doing a Lazarus.Towns03 said:550 shares collecting dust here too. what's the news?South Platte said:Bagholder, from a while agoconfucius_ag said:
Old name from a while ago is trying to break out above 200ma ------ASAN
